New techniques in the radiotherapeutic treatment of gynecological malignancies

Current Opinion in Obstetrics and Gynecology

Volumn 10, Issue 1, 1998, Pages 21-28

  DesRosiers, Paul M ^a   Cardenes, Higinia ^a,b   Woodburn, Robert ^a   Randall, Marcus E ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; HYDROXYUREA; MITOMYCIN C; PLACEBO;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GYNECOLOGIC CANCER; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURGICAL TECHNIQUE; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA; VULVA CARCINOMA;

EID: 0031913694     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199802000-00005     Document Type: Review

References (54)

1. Finan MA, DeCesare S, Fiorica JV, Chambers R, Huffman MS, Kline RC, et al. Radical hysterectomy for stage 1B1 vs 1B2 carcinoma of the cervix: does the new staging system predict morbidity and survival? Gynecol Oncol 1985; 62:139-147. A total of 229 patients with stage IB cervical carcinoma treated with radical hysterectomy were assigned to the new FIGO sub-stages IB1 (n=181) and IB2 (n=48) based on clinical tumor diameter. Stage IB2 did have a significantly worse five-year survival rate (72.8%) when compared with stage IB1 (90.0%) (P=0.0265). Of the stage IB2 patients, 72% required adjuvant radiation therapy.
2. Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage 1B squamous cell carcinoma of the uterine cervix. Int J Radiation Oncol Biol Phys 1994; 29:9-16.
3. Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage 1B carcinoma of the cervix. Int J Radiation Oncol Biol Phys 1995; 32:1289-1300.
4. Curtin JP. Radical hysterectomy - the treatment of choice for early-stage cervical carcinoma [Editorial]. Gynecol Oncol 1996; 62:137-138.
5. Sevin BU, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli OR, Averette HE. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 1995; 76(Suppl 10):1978-1986.
6. Sevin BU, Lu Y, Bloch DA, Nadji M, Koechli OR, Averette HE. Surgically defined prognostic parameters in patients with early cervical carcinoma, a multivariate survival tree analysis. Cancer 1996; 78:1438-1446.
7. Moore DH, Stehman FH. What is the appropriate management of early stage cervical cancer (International Federation of Gynecology and Obstetrics stages I and IIA), surgical assessment of lymph nodes, and role of therapeutic resection of lymph nodes involved with cancer? [Review]. J Natl Cancer Inst 1996; 21:43-46.
8. Zreik TG, Chambers JT, Chambers SK. Parametrial involvement, regardless of nodal status: a poor prognostic factor for cervical cancer. Obstet Gynecol 1996; 87:741-746. After radical hysterectomy, patients with parametrial involvement had shorter disease-free intervals, regardless of whether lymph nodes were positive or not; also, adenocarcinoma was worse prognostically.
9. Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby P, Cooper J, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinoma. Ten-year treatment results of RTOG 79-20. JAMA 1995; 274:387-393.
10. Vasilev SA, McGonigle KF. Extraperitoneal laparoscopic para-aortic lymph node dissection. Gynecol Oncol 1996; 61:315-320. In this paper, an extraperitoneal laparoscopic technique for para-aortic lymph node dissection was developed in pigs followed by a bilateral procedure in four human subjects. A mean of five nodes were removed (range 1-9). Operative times ranged from 120 to 140 minutes.
11. Clough KB, Goffinet F, Labib A, Renolleau C, Campana F, de la Rochefordiere A, Durand JC, Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases. Cancer 1996; 77:2638-2645.
12. Kim RY, McGinnis LS, Spencer SA, Meredith RF, Jennelle RLS, Merle MS. Conventional four-field pelvic radiotherapy technique without CT treatment planning in cancer of the cervix: potential geographic miss. Radiother Oncol 1994; 30:140-145.
13. Bonin SR, Lanciano RM, Corn BW, Hogan WM, Hartz WH, Hanks GE. Bony landmarks are not an adequate substitute for lymphangiogram in defining pelvic lymph node location for the treatment of cervical cancer with radiotherapy, Int J Radiation Oncol Biol Phys 1996; 34:167-172.
14. Greer BE, Koh WJ, Stelzer KJ, Goff BA, Comsia N, Tran A. Expanded pelvic radiotherapy fields for treatment of local-regionally advanced carcinoma of the cervix: outcome and complications. Am J Obstet Gynecol 1996; 174:1141-1149. This technique employs larger fields in a four-field box arrangement, minimizing the possibility of missing the tumor or lymph nodes with the radiation fields. The four-year disease-specific survival rates were 76% for stage IIB and 53% for stage III. The grade 3 or higher rectal complication rate was 9%, while the overall grade 3 or higher complication rate was 14.8%.
15. Kim RY, Caranto JF, Pareek PN, Virostek LJ. Dynamics of pear-shaped dimensions and volume of intracavitary brachytherapy in cancer of the cervix: a desirable pear shape in the era of three-dimensional treatment planning, Int J Radiation Oncol Biol Phys 1997; 37:1193-1199.
16. Hall EJ. Radiobiology for the Radiologist, 4th edn. Philadelphia: J.B. Lippincott Company; 1994. pp. 115-124.
17. Cox JD. Moss' Radiation Oncology: Rationale, Technique, Results, 7th edn. Mosby Year Book, Inc.; 1994. pp. 651-653.
18. Shigematsu Y, Nishiyami K, Masaki N. Treatment of carcinoma of the uterine cervix by remotely controlled afterloading intracavitary radiotherapy with high dose-rate: a comparative study with a low dose-rate system, Int J Radiation Oncol Biol Phys 1983; 9:351-356.
19. Rodrigus P, De Winter K, Venselaar JLM, Leers WH, Evaluation of late morbidity in patients with carcinomas of the utenne cervix following a dose rate change. Radiother Oncol 1997; 42:137-141. This study supports clinically the radiobiologic 'dose-rate effect'; a slight increase in the brachytherapy dose-rate, even at a lower dose, had a measurable increase in late-occurring side-effects.
20. Eifel PJ. High-dose-rate brachytherapy for carcinoma of the cervix: high tech or high risk? [Editorial]. Int J Radiation Oncol Biol Phys 1992; 24:383-386.
21. Hart K, Han I, Deppe G, Malviya V, Malone J Jr, Christensen C, Chuba P et al. Postoperative radiation for cervical cancer with pathologic risk factors. Int J Radiation Oncol Biol Phys 1997; 37:833-838.
22. Han I, Malvita V, Chuba P, Orton C, Devi S, Deppe G, Malone J Jr, et al. Multifractionated high-dose-rate brachytherapy with concomitant daily teletherapy for cervical cancer. Gynecol Oncol 1996; 63:71-77.
23. Swift PS, Purser P, Roberts LW, Pickett B, Powell CB, Phillips TL. Pulsed low dose rate brachytherapy for pelvic malignancies, Int J Radiation Oncol Biol Phys 1997; 37:811-817.
24. Sundfor K, Trope CG, Hogberg T, Onsrud M, Koern J, Simonsen E, Bertelsen K, et al. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma: a randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer 1996; 77:2371-2378. This prospective randomized trial showed no benefit for neoadjuvant chemotherapy with 5-FU/cisplatin.
25. Sardi J, Giaroli A, Sananes C, Rueda NG, Vighi S, Ferreira M, Bastardas G, et al. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri: an unexpected therapeutic management, Int J Gynecol Cancer 1996; 6:85-93. Neoadjuvant 'quick VBC', three cycles of vincristine, bleomycin and cisplatin given 10 days apart, was followed by either RT alone or surgery+RT. The three-modality arm had a survival advantage that may be due to extended field RT in pathologically confirmed positive peri-aortic lymph nodes.
26. Stehman FB, Bundy BN. Carcinoma of the cervix treated with chemotherapy and radiation therapy: cooperative studies in the gynecologic oncology group. Cancer 1993; 71:1697-1701.
27. Fields AL, Anderson PS, Goldberg GL, Walder S, Bettler J, Sood B, Runowicz CD. Mature results of a phase II trial of concomitant cisplatin/ pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 1996; 61:416-422.
28. Madhu J, Flam M, Caplan R, Rotman M, Quivey J, Steinfeld A, Russell A. Final results of a phase II chemoradiation protocol for locally advanced cervical cancer: RTOG 85-15. Gynecol Oncol 1996; 61:221-226.
29. Muderspach LI, Curtin JP, Roman LD, Gebhardt JA, Klement V, Qian D, Morrow CP, et al. Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study. Gynecol Oncol 1997; 65:336-342.
30. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R. Prognostic factors for groin metastasis in squamous cell carcinoma of the vulva (A Gynecologic Oncology Group Study). Gynecol Oncol 1993; 49:279-283.
31. Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groins. Obstet Gynecol 1986; 68:733-740.
32. Manavi M, Berger A, Kucera E, Vavra N, Kucera H. Does T1, NO-1 vulvar cancer treated by vulvectomy but not lymphadenectomy need inguinofemoral radiation? Int J Radiation Oncol Biol Phys 1997; 38:749-753.
33. Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW. Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiation Oncol Biol Phys 1997; 38:381-389.
34. Lupi G, Raspagliesi F, Zucali R, Fontanelli R, Paladini D, Kenda R, di Re F. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. Cancer 1996; 77:1472-1478.
35. Landoni F, Maneo A, Zanetta G, Colombo A, Nava S, Placa F, Tancini G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin-C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol 1996; 61:321-327.
36. Erfel PJ, Morris M, Burke TW, Levenback C, Gershenson DM. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol 1995; 59:51-56.
37. Chyle V, Zagars GK, Wheeler JA, Wharton JT, Delclos L. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiation Oncol Biol Phys 1996; 35:891-905. This retrospective analysis of 301 patients with vaginal cancer treated at MD Anderson provides treatment parameters and outcomes with a median follow-up of 13 years. Tumor bulk and failure to achieve local control were independent determinants of metastatic relapse. The major determinants of local control were FIGO stage, tumor size, location (upper better than others) and circumferential involvement (posterior being worse). Non-clear cell adenocarcinoma was much worse prognostically than squamous cell carcinoma.
38. Kirkbride P, Fyles A, Rawlings GA, Manchul L, Levin W, Murphy KJ, Simm J. Carcinoma of the vagina - experience at the Princess Margaret Hospital (1974-1989). Gynecol Oncol 1995; 56:435-443.
39. Ali MM, Huang DT, Goplerud DR, Howells R, Lu JD. Radiation alone for carcinoma of the vagina. Variation in response related to the location of the primary tumor. Cancer 1996; 77:1934-1939.
40. Stock RG, Chen ASJ, Seski J. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 1995; 56:45-52.
41. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecological cancer. Corpus cancer staging, Int J Gynecol Obstet 1989; 28:189-190.
42. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma. The importance of the distinction between surgical stage and clinical stage - A Gynecologic Oncology Group Study. Cancer 1996; 77:1115-1121. Of 819 women with clinical stage I and occult stage II endometrial cancer, 597 had surgical stage I or II (27% were upstaged). Age, depth of myometrial invasion, and to a lesser extent, histologic grade and cell type were independent prognostic variables.
43. Yokoyama Y, Maruyama H , Sato S, Saito Y. Indispensability of pelvic and periaortic lymphadenectomy in endometrial cancers. Gynecol Oncol 1997; 64:411-417.
44. Descamps P, Calais G, Moire C, Bertrand P, Castiel M, Le Floch O, Lancac J, et al. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy. Gynecol Oncol 1997; 64:54-58.
45. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40:55-65.
46. Greven KM, Corn BW, Case D, Purser P, Lanciano R. Which prognostic factors Influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation? Int J Radiation Oncol Biol Phys 1997; 39:413-418.
47. Mayr NA, Wen B, Benda JA, Sorosky JI, Davis CS, Fuller RW, Hussey DH. Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical and lower uterine segment involvement. Patterns of failure. Radiology 1995; 196:323-328.
48. Algan O, Tabesh T, Hanlon A, Hogan WM, Boente M, Lanciano RM. Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II endometrial cancer, Int J Radiation Oncol Biol Phys 1996; 35:925-933.
49. Ahmad NR, Lanciano RM, Corn BW, Schultheiss T. Postoperative radiation therapy for surgically staged endometrial cancer: impact of time factors (overall treatment time and surgery-to-radiation interval) on outcome. Int J Radiation Oncol Biol Phys 1995; 33:837-842.
50. Rush S, Gal D, Potters L, Bosworth J, Lovecchio J, Pelvic control following external beam radiation for surgical stage I endometrial carcinoma. Int J Radiation Oncol Biol Phys 1995; 33:851-854.
51. Eltabbakh GH, Piver MS, Hempling RE, Shin KH, Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial, Int J Radiation Oncol Biol Phys 1997; 38:373-380.
52. Larson DM, Connor GP, Broste SK, Krawisz BR, Johnson KK. Prognostic significance of gross myometrial invasion with endometrial cancer. Obstet Gynecol 1996; 88:394-398.
53. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 1980; 56:419-426.
54. Reisinger SA, Asbury R, Liao S-Y, Homesley HD, A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma. A Gynecologic Oncology Group pilot study. Gynecol Oncol 1996; 63:299-303.